CN114269779B - 抗bag2抗体和治疗癌症的方法 - Google Patents

抗bag2抗体和治疗癌症的方法 Download PDF

Info

Publication number
CN114269779B
CN114269779B CN202080027907.0A CN202080027907A CN114269779B CN 114269779 B CN114269779 B CN 114269779B CN 202080027907 A CN202080027907 A CN 202080027907A CN 114269779 B CN114269779 B CN 114269779B
Authority
CN
China
Prior art keywords
antibody
seq
xaa
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080027907.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114269779A (zh
Inventor
金圣镇
D·W·康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medpacto Inc
Original Assignee
Medpacto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190016347A external-priority patent/KR102172541B1/ko
Priority claimed from KR1020190016359A external-priority patent/KR102241558B1/ko
Application filed by Medpacto Inc filed Critical Medpacto Inc
Publication of CN114269779A publication Critical patent/CN114269779A/zh
Application granted granted Critical
Publication of CN114269779B publication Critical patent/CN114269779B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080027907.0A 2019-02-12 2020-02-12 抗bag2抗体和治疗癌症的方法 Active CN114269779B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1020190016347A KR102172541B1 (ko) 2019-02-12 2019-02-12 Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법
KR10-2019-0016347 2019-02-12
KR10-2019-0016359 2019-02-12
KR1020190016359A KR102241558B1 (ko) 2019-02-12 2019-02-12 Bag2 폴리펩티드 또는 이의 단편에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
PCT/IB2020/051136 WO2020165794A1 (en) 2019-02-12 2020-02-12 Anti-bag2 antibody and methods of treating cancer

Publications (2)

Publication Number Publication Date
CN114269779A CN114269779A (zh) 2022-04-01
CN114269779B true CN114269779B (zh) 2025-05-09

Family

ID=72044199

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080027907.0A Active CN114269779B (zh) 2019-02-12 2020-02-12 抗bag2抗体和治疗癌症的方法
CN202080028383.7A Active CN114761803B (zh) 2019-02-12 2020-02-12 使用抗bag2抗体诊断癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080028383.7A Active CN114761803B (zh) 2019-02-12 2020-02-12 使用抗bag2抗体诊断癌症的方法

Country Status (11)

Country Link
US (2) US12122822B2 (https=)
EP (2) EP3938788A4 (https=)
JP (4) JP7706154B2 (https=)
CN (2) CN114269779B (https=)
AU (1) AU2020222326B2 (https=)
BR (1) BR112021015940A2 (https=)
CA (1) CA3129748A1 (https=)
MX (1) MX2021009690A (https=)
SG (1) SG11202108140SA (https=)
WO (2) WO2020165797A1 (https=)
ZA (1) ZA202106551B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560537B2 (en) 2002-09-30 2009-07-14 Ludwig Institute For Cancer Research Human sarcoma-associated antigens
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
JP2008518629A (ja) 2004-11-08 2008-06-05 シェーリング コーポレイション Ｍｄｌ−１の腫瘍との関連およびその方法
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
EP2142670A1 (en) * 2007-04-05 2010-01-13 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
JP6637290B2 (ja) * 2015-11-05 2020-01-29 武 永安 Ｃｋ１９に特異的なモノクローナル抗体およびこれを産生するハイブリドーマ、癌の検出キット、癌の検出方法および癌の転移の判定方法
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
KR102039624B1 (ko) * 2017-03-03 2019-11-01 재단법인 차세대융합기술연구원 BAG2 및 Cathepsin B 상호결합 억제 물질 스크리닝 방법
KR102230314B1 (ko) * 2017-10-24 2021-03-22 주식회사 메드팩토 혈액으로부터 암을 진단하는 방법
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Co-chaperone BAG2 Determines the Pro-oncogenic Role of Cathepsin B in Triple-Negative Breast Cancer Cells;Kyung-Min Yang等;Cell Rep;第21卷(第10期);图1、图3-4、图7、第2953-2954页、补充实验数据 *

Also Published As

Publication number Publication date
JP2022521706A (ja) 2022-04-12
AU2020222326B2 (en) 2026-03-19
JP7747268B2 (ja) 2025-10-01
JP2025071090A (ja) 2025-05-02
EP3938788A4 (en) 2023-01-04
WO2020165794A1 (en) 2020-08-20
MX2021009690A (es) 2021-10-01
JP2022525843A (ja) 2022-05-20
CA3129748A1 (en) 2020-08-20
JP7706154B2 (ja) 2025-07-11
CN114269779A (zh) 2022-04-01
EP3924382A4 (en) 2023-01-04
BR112021015940A2 (pt) 2021-10-05
CN114761803B (zh) 2025-09-05
ZA202106551B (en) 2024-12-18
JP2025071822A (ja) 2025-05-08
US20230183324A1 (en) 2023-06-15
CN114761803A (zh) 2022-07-15
EP3938788A1 (en) 2022-01-19
US20230194534A1 (en) 2023-06-22
US12583915B2 (en) 2026-03-24
WO2020165797A1 (en) 2020-08-20
EP3924382A1 (en) 2021-12-22
AU2020222326A1 (en) 2021-08-19
US12122822B2 (en) 2024-10-22
SG11202108140SA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
JP6952736B2 (ja) 抗ｃｇｒｐ組成物およびその使用
TWI432452B (zh) 針對ｈｅｒ-３之抗體類及其用途
CN110914302A (zh) 可活化抗pdl1抗体及其使用方法
EP3741777A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN115551895A (zh) 抗ccr8剂
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
US20210346485A1 (en) Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
KR20150100848A (ko) 항-lamp1 항체와 항체 약물 접합체 및 이의 용도
US20250326851A1 (en) Medical use of ccr8 antibodies and dosing schedule
EP4257612A1 (en) Development of new tumor engager therapeutic drug and use thereof
TW202202170A (zh) 治療多發性骨髓瘤之方法
CN116249717A (zh) 识别分拣蛋白的抗体
CN119317646A (zh) 抗liv-1抗体及其药物偶联物
JP2025071822A (ja) 抗ｂａｇ２抗体および癌を治療する方法
CN115698075A (zh) 涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗
JP2022523656A (ja) Ｔ細胞リンパ腫の処置
EP4725966A1 (en) Human epidermal growth factor 3 antibody, preparation method therefor, and use thereof
RU2815586C2 (ru) Антитело к bag2 и способы лечения онкологического заболевания
WO2025064690A1 (en) High affinity antibodies recognizing core 2 o-glycans of variant muc5ac antigen, compositions containing and uses thereof
CN114773485A (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
WO2013177386A1 (en) Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant